Investigation of antimicrobial use and the impact of antimicrobial use guidelines in a small animal veterinary teaching hospital: 1995-2004

Journal of the American Veterinary Medical Association

Volumn 228, Issue 4, 2006, Pages 553-558

  Weese, J Scott ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COTRIMOXAZOLE; GLYCOPEPTIDE; LINCOSAMIDE DERIVATIVE; MACROLIDE; METRONIDAZOLE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE;

CAT; DOG; DRUG USE; INTENSIVE CARE; NONHUMAN; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; REVIEW; TEACHING HOSPITAL; VETERINARY MEDICINE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CAT DISEASES; CATS; DOG DISEASES; DOGS; DRUG UTILIZATION; HOSPITALS, ANIMAL; HOSPITALS, TEACHING; ONTARIO; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

ANIMALIA; CANIS FAMILIARIS;

EID: 32544431749     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.228.4.553     Document Type: Review

References (26)

1. Martin C, Ofotokun I, Rapp R, et al. Results of an antimicrobial control program at a university hospital. Am J Health Syst Pharm 2005;62:732-738.
2. Murthy R. Implementation of strategies to control antimicrobial resistance. Chest 2001;119:405S-411S.
3. Gonzales R, Malone DC, Maselli JH, et al. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis 2001;33:757-762.
4. Bantar C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings and bacterial resistance. Clin Infect Dis 2003;37:180-186.
5. Lee J, Carlson JA, Chamberlain MA. A team approach to hospital formulary replacement. Diagn Microbiol Infect Dis 1995;22: 239-242.
6. Sunenshine RH, Liedtke LA, Jernigan DB, et al. Role of infectious diseases consultants in management of antimicrobial use in hospitals. Clin Infect Dis 2004;38:934-938.
7. White AC Jr, Atmar RL, Wilson J, et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25: 230-239.
8. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-1433.
9. Schentag JJ, Ballow CH, Fritz AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993;16:255-264.
10. Regal RE, DePestel DD, VadenBussche HL: The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to β-lactams in a large teaching hospital. Pharmacotherapy 2003;23:618-624.
11. John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471-485.
12. Prescott JF, Hanna WJ, Reid-Smith R, et al. Antimicrobial drug use and resistance in dogs. Can Vet J 2002;43:107-116.
13. Rantala M, Holso K, Lillas A, et al. Survey of condition-based prescribing of antimicrobial drugs for dogs at a veterinary teaching hospital. Vet Rec 2004;155:259-262.
14. Odensvik K, Grave K, Greko C. Antibacterial drugs prescribed for dogs and cats in Sweden and Norway 1990-1998. Acta Vet Scand 2001;42:189-198.
15. AVMA. Judicious therapeutic use of antimicrobials. Available at: www.avma.org/scienact/jtua/jtua98.asp. Accessed Apr 11, 2005.
16. Canadian Veterinary Medical Association. Canadian Veterinary Medical Association guidelines on the prudent use of antimicrobial drugs in animals. Available at: www.canadianveterinarians.net/pdfFiles/AMRGuidelines.pdf. Accessed Mar 15, 2005.
17. Capella D. Descriptive tools and analysis. In: Dukes MNG, ed. Drug utilization studies: methods and uses. Copenhagen: WHO Regional Publications, European Series, WHO Regional Office for Europe, 1993;55-78.
18. Bakken JS. The fluoroquinolones: how long will their utility last? Scand J Infect Dis 2004;36:85-92.
19. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 2001;33(suppl 3):S187-S192.
20. Pena C, Albareda JM, Pallares R, et al. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520-524.
21. Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis 2002;35:1505-1511.
22. Thwaites RT, Frost JA. Drug resistance in Campylobacter jejuni, C coli, and C lari isolated from humans in north west England and Wales, 1997. J Clin Pathol 1999;52:812-814.
23. Piddock LJ. Fluoroquinolone resistance: overuse of fluoroquinolones in human and veterinary medicine can breed resistance. BMJ 1998;317:1029-1030.
24. Mortensen EM, Restrepo M, Anzueto A, et al. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004;117:726-731.
25. Jarvis WR. Controlling healthcare-associated infections: the role of infection control and antimicrobial use practices. Semin Pediatr Infect Dis 2004;15:30-40.
26. Weese JS, Armstrong J. Outbreak of Clostridium difficile-associated disease in a small animal veterinary teaching hospital. J Vet Intern Med 2003;17:813-816.